Investigation of In-vitro Antiproliferative activity of Ampelocissus latifolia root extract on MCF-7 breast cancer cells Ampelocissus latifolia root extract against MCF-7 breast cancer cells.

Author:

Viswanathan Nidarsan1,Gowri V1,Punnagai K1

Affiliation:

1. Department of Pharmacology, Sri Ramachandra Institute of Higher Education and Research (Deemed to be University), SRIHER, No.1, Ramachandra Nagar, Porur, Chennai, Tamil Nadu 600116.

Abstract

Background: Breast cancer is one of the leading causes of cancer related death in women worldwide. Treatment of cancer has been plagued with toxic side effects of anticancer drugs. The need of the hour is the development of novel compounds with maximum cytotoxic effect on cancer cells with minimal toxicity to normal cells. The current direction of researchers worldwide is to identify anticancer compounds from natural sources. In India, traditional medicine has employed use of herbaceous climbers of grape family for treatment of ailments ranging from snakebites to diabetes. In the current study, an attempt has been made to explore the in vivo antiproliferative property of ethanolic extract of root of Ampelocissus latifolia against MCF-7 breast cancer cell line. Materials and Methods: The antiproliferative effect of Ethanolic extract of root of Ampelocissus latifolia (ERAL) was estimated by 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl--tetrazolium bromide (MTT) assay. The MCF -7 cell viability in various concentrations of ERAL including 7.8mcg/ml, 15.6mcg/ml, 31.2mcg/ml, 62.5mcg/ml, 125mcg/ml, 250mcg/ml, 500mcg/ml and 1000mcg/ml was tested. The IC50 value was calculated. All the experiments were done in triplicates. This was followed up with DNA fragmentation assay and fluorescent staining and microscopy. Results: The MCF -7 cell viability in various concentration of ERAL including 7.8mcg/ml, 15.6mcg/ml, 31.2mcg/ml ,62.5mcg/ml, 125mcg/ml, 250mcg/ml, 500mcg/ml and 1000mcg/ml was found to be 69.01%, 62.39%, 55.04%, 48.00%, 41.17%, 33.82%, 26.78% and 20.06% respectively .The IC50 concentration was found to be in the range of 62.5mcg/ml.The cell viability was found to be dose dependant.DNA fragmentation assay and DAPI and PI staining of cells treated with IC50 concentration of ERAL were indicative of significant cell death. Conclusion: The concentration dependent inhibition of MCF-7 cells supported by DNA fragmentation and fluorescent staining indicate that Ampelocissus latifolia can be a source of novel anticancer molecules.

Publisher

A and V Publications

Subject

Pharmacology (medical),Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Reference42 articles.

1. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1736-1788. doi: 10.1016/S0140-6736(18)32203-7. Epub 2018 Nov 8. Erratum in: Lancet. 2019 Jun 22;393(10190):e44. Erratum in: Lancet. 2018 Nov 17;392(10160):2170. PMID: 30496103; PMCID: PMC6227606.

2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313. PMID: 30207593.

3. World Health Organization. Cancer. 2018 september 12. Available from https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed: 31/1/2021.

4. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf accessed [31/01/2021].

5. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3